Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 31

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 31
---
Our pending patent applications may not result in issued patents, and any patents that may be granted could include only limited claims. As a result, our intellectual property protection may be weaker than anticipated, which could make it more difficult for us to establish or maintain a competitive position.

The patent application process is subject to numerous risks and
uncertainties, and there can be no assurance that we will be successful in protecting our drug candidates by obtaining and defending
patents. We have pending and issued U.S. and foreign patents and patent applications covering our drug candidates; however, we cannot
predict:

| ● | if                                                           
 and when patents nay issue based on our patent applications; |

| ● | the                                                                         
 scope of protection of any patent issuing based on our patent applications; |

| ● | whether                                                                      
 the claims of any issued patent will provide protection against competitors; |

| ● | whether                                                                                    
 we will need to initiate litigation or administrative proceedings to enforce and/or defend 
 our patent rights which will be costly whether we win or lose; and/or                      |

| ● | whether                                                                                  
 the patent applications will result in issued patents with claims that cover each of our 
 drug candidates or uses thereof in the United States or in other foreign countries.      |

We may be subject to a third-party pre-issuance
submission of prior art to the USPTO or become involved in post-grant review procedures, oppositions, derivations, revocation, reexaminations,
inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights
of others. An adverse determination in any such challenge may result in loss of exclusivity or in our patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical
technology and products or limit the duration of the patent protection of our technology and products. Such challenges also may result
in substantial costs and require significant time from our scientists and management, even if the eventual outcome is favorable to us.
Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.
Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the
outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.

We may rely on more
than one patent to provide multiple layers